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ABSTRACT Sensing of and responding to environmental changes are of vital importance for microbial cells. Consequently, bac-
teria have evolved a plethora of signaling systems that usually sense biochemical cues either via direct ligand binding, thereby
acting as “concentration sensors,” or by responding to downstream effects on bacterial physiology, such as structural damage to
the cell. Here, we describe a novel, alternative signaling mechanism that effectively implements a “flux sensor” to regulate antibi-
otic resistance. It relies on a sensory complex consisting of a histidine kinase and an ABC transporter, in which the transporter
fulfills the dual role of both the sensor of the antibiotic and the mediator of resistance against it. Combining systems biological
modeling with in vivo experimentation, we show that these systems in fact respond to changes in activity of individual resistance
transporters rather than to changes in the antibiotic concentration. Our model shows that the cell thereby adjusts the rate of de
novo transporter synthesis to precisely the level needed for protection. Such a flux-sensing mechanism may serve as a cost-
efficient produce-to-demand strategy, controlling a widely conserved class of antibiotic resistance systems.
IMPORTANCE Bacteria have to be able to accurately perceive their environment to allow adaptation to changing conditions. This
is usually accomplished by sensing the concentrations of beneficial or harmful substances or by measuring the effect of the pre-
vailing conditions on the cell. Here we show the existence of a new way of sensing the environment, where the bacteria monitor
the activity of an antibiotic resistance transporter. Such a “flux-sensing” mechanism allows the cell to detect its current capacity
to deal with the antibiotic challenge and thus precisely respond to the need for more transporters. We propose that this is a cost-
efficient way of regulating antibiotic resistance on demand.
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Sensing of and responding to environmental changes are ofvital importance for microbial cells, as they facilitate their fine-
tuned adaptation to prevailing conditions. The range of parame-
ters a single cell can monitor is immense, including conditions as
diverse as nutrient supply, oxygen levels, temperature, pH, cell
densities, and presence of toxic compounds. It is therefore hardly
surprising that bacteria have developed a plethora of sensory and
regulatory strategies to accomplish this feat. In the specific context
of antibiotic resistance, bacteria have to be able to accurately de-
termine the severity of the attack in order to decide on an adequate
response. The precision of this response is key to both survival of
antimicrobial action and minimizing the metabolic cost of resis-
tance (1, 2).
One common feature of controlling a cellular response is to
monitor the ambient concentration of a specific substance. In the
case of antibiotic resistance, this can be achieved, e.g., via direct
binding to a sensory protein, such as the vancomycin-responsive
histidine kinase (HK) VanSsc of Streptomyces coelicolor (3). An
alternative approach is to monitor the cellular damage caused by
the antibiotic, as is the case, e.g., for the LiaRS cell envelope
damage-sensing system of Bacillus subtilis (4). Such an indirect
sensing strategy allows the cell to integrate into its response its
current physiological state, which can significantly influence the
potency of a given concentration of antibiotic. For instance, fast-
growing cells are usually much more susceptible to antibiotic ac-
tion than slow-growing cells. While a damage-sensing strategy
undoubtedly provides a more context-dependent response, it re-
quires the accumulation of a certain degree of cellular damage.
Here, we present evidence for a third, previously undescribed reg-
ulatory strategy, allowing the bacterium to directly monitor its
current capacity to deal with the antibiotic threat by measuring
the activity of a drug efflux pump (referred to as “flux sensing”).
We recently showed that a unique type of ATP-binding cassette
(ABC) transporters is actively involved in a signaling pathway
controlling its own production (5–7). These transporters mediate
resistance against a wide range of antimicrobial peptides in many
Gram-positive species, including important pathogens, such as
Staphylococcus aureus and Enterococcus faecalis (8). Their expres-
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sion is regulated by two-component systems whose HKs lack dis-
cernible ligand-binding domains and instead form a sensory com-
plex with the transporter (9, 10). The signaling process is best
understood in Bacillus subtilis, where the two-component system
BceRS and its associated ABC-transporter BceAB together sense
and counteract the deleterious effects of bacitracin and several
other antimicrobial peptides interfering with the lipid II cycle of
cell wall biosynthesis, by triggering a 500-fold increase in the ex-
pression of the bceAB transporter operon (5, 9, 11) (Fig. 1a).
To characterize the regulatory role of the transporter, here we
took a systems approach, combining mathematical modeling with
experiments probing the time-resolved, dose-dependent response
of the Bce system to its substrate bacitracin. We show that signal-
ing within the Bce system operates by a flux-sensing mechanism,
monitoring the activity of individual transporters. Our model al-
lowed us to derive a unique response signature for a flux sensor,
which was experimentally validated. Moreover, the model was
able to predict the antibiotic sensitivity of cells depending on
transporter expression, leading us to propose that flux sensing
serves as a novel produce-to-demand strategy to control antibiotic
resistance in changing environments.
RESULTS
ABC transporter production rapidly adapts to a wide range of
bacitracin inputs. To obtain detailed quantitative information on
the regulatory dynamics of the Bce system, we first studied the
relationship between the external antibiotic concentration and the
transcriptional response of the target promoter PbceA. To this end,
exponentially growing SGB073 cells (wild-type B. subtilis carrying
a chromosomally integrated PbceA-luxABCDE reporter) were ex-
posed to sublethal concentrations of bacitracin. At virtually all
bacitracin concentrations tested, luciferase activity initially rose
rapidly upon antibiotic addition, before leveling off to reach a
plateau 20 to 30 min after induction (Fig. 2A). A plot of the plateau
level against antibiotic concentration revealed that the system’s
response quickly adapted to a wide dynamic range of antibiotic
FIG 1 Schematic of conceivable sensory scenarios employed by the BceRS-BceAB system. In an external sensing scenario (a), the ABC transporter BceAB might
act as a scaffold that keeps the histidine kinase BceS in an active conformation, which would allow BceS to perceive the extracellular concentration of bacitracin
(red symbols). Since up-regulation of BceAB is not expected to change the extracellular concentration of bacitracin, the rate of gene expression should be
independent of the BceAB level in this scenario (no feedback). In an internal sensing scenario (b), BceAB might be required to translocate bacitracin into the
cytoplasm where BceS could sense its abundance. Here, up-regulation of BceAB should lead to an increased rate of bacitracin influx, which would in turn lead
to further up-regulation of BceAB expression (positive feedback). In a flux-sensing scenario (c), BceAB itself is the true sensor, which directly signals its transport
activity to BceS. In such a scenario, up-regulation of BceAB would reduce the load experienced by each individual transporter and thereby reduce signaling via
BceS (negative feedback). (d) Schematic depiction of the expected impact of different levels of the BceAB transporter (low, red curves; high, green curves) on
dose-dependent PbceA activity.
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input (0.1 to 100 g/ml bacitracin) (Fig. 2B). Such gradual, ho-
meostatic control of target gene expression is often found in reg-
ulatory systems that exploit negative-feedback mechanisms, while
positive-feedback regulation frequently enables switch-like or
even hysteretic responses (12). The presence of a negative feed-
back mechanism was also suggested by our observation that the
PbceA promoter activity reached its steady-state value within a
short time (20 to 30 min) (Fig. 2A) relative to the cell doubling
time of ~70 min (see Fig. S1 in the supplemental material), as
negative-feedback control is known to reduce the response time of
genetic circuits (13).
To elucidate the source of this apparent feedback effect, we
considered three plausible roles of the transporter in the regula-
tory pathway. (i) In the simplest scenario, the transporter acts as a
mere ligand-binding component in a sensory complex with the
HK, as is the case in regulation of sugar phosphate uptake by the
Uhp system in Escherichia coli (14, 15). The input signal for such a
system is the ambient concentration of the cognate substrate
(Fig. 1a). This signal will not change if the number of transporters
inserted in the membrane increases, since the amount of HK, and
hence the number of sensory complexes, remains constant. Thus,
there will be no feedback on regulation. (ii) Alternatively, the
transporter might be required to translocate the substrate to a
cytoplasmic recognition site (Fig. 1b). Such a strategy is realized,
e.g., in the regulation of arabinose utilization by E. coli (16), where
the level of intracellular substrate serves as the input signal. While
the polarity of BceAB-mediated transport is not known, it has
been suggested that BceAB may act as an importer of bacitracin,
releasing it into the cytoplasm for degradation (5, 8). Here, the
strength of the stimulus should increase during the induction pro-
cess, because the amount of bacitracin transported into the cell
will rise with the supply of transporters, thus creating a positive
feedback on the response. (iii) The third conceivable scenario is
that the HK activity is determined by the rate of flux through
individual transporters (Fig. 1c). BceAB has also been proposed to
act as a “hydrophobic vacuum cleaner” (17), conferring resistance
by clearing the target from the inhibitory grip of the antibiotic
(Fig. 1c) (7, 18). In such a scenario, increasing BceAB copy num-
bers should alleviate the load experienced by individual transport-
ers (Fig. 1c), resulting in a negative feedback of BceAB on its own
expression. Thus, qualitatively, a flux-sensing scenario best re-
flects the observed dynamics of PbceA activation.
The behavior of the wild-type system is compatible with a
mathematical model for relative flux sensing. To test if the pro-
posed flux-sensing mechanism can quantitatively explain the reg-
ulatory dynamics in the Bce system, we developed a mathematical
model, incorporating signal transduction via such a mechanism.
Bacitracin is known to bind to its membrane-associated target
molecule undecaprenol-pyrophosphate (UPP), thus blocking the
dephosphorylation and recycling of UPP in the lipid II cycle of cell
wall biosynthesis (19). If we suppose that the ABC transporter
BceAB catalyzes the release of bacitracin from UPP with
Michaelis-Menten enzyme kinetics, the time-dependent concen-
tration of the bacitracin-bound form of UPP, UPP-bac, can be
described by a differential equation of the form
d
dt
UPP-bac  konbacUPPtot  UPP-bac
 koff UPP-bac  vmaxJbacBceAB (1)
Here, [bac] is the externally applied bacitracin concentration,
kon and koff are the spontaneous on and off rates for the binding of
bacitracin to UPP, UPPtot is the total UPP level in the cell, Jbac 
[UPP-bac]/(Km  [UPP-bac]) is the relative bacitracin load per
BceAB transporter, and vmax and Km are the maximal transport
rate and Michaelis-Menten constant of BceAB, respectively (see
Tables S1 and S2 in the supplemental material).
To implement the proposed flux-sensing mechanism in our
model, we took into account that the expression of the two-
component system operon bceRS is constitutive (see Fig. S2 in the
supplemental material) and also that the interaction between the
histidine kinase BceS and the BceAB transporter is bacitracin in-
dependent (9). Moreover, we verified that the overproduction of
BceS did not significantly affect the MIC of a strain with constitu-
tive BceAB expression (see Fig. S3 in the supplemental material),
indicating that the transport activity of BceAB is not affected by
the formation of the sensory complex with BceS in vivo. Thus, as
long as BceAB molecules outnumber BceS molecules, so that BceS
is the limiting component in complex formation, there should be
a constant number of functional BceS-BceAB sensory complexes
in the cell, while the number of free BceAB transporters should
change with increasing total transporter levels. Under inducing
conditions this is a safe assumption, because we can readily detect
the presence of BceAB, but not of BceS, using Western blotting or





















































FIG 2 Gene expression driven by the PbceA promoter rapidly adapts to a wide
range of antibiotic concentrations. (A) Exponentially growing cells of strain
SGB073 were exposed to sublethal concentrations of bacitracin at 0 min, and
luciferase activity from a PbceA-luxABCDE reporter construct was monitored
over time. Data are means and standard deviations for at least three indepen-
dent biological replicates (lower error bars are not depicted if negative values
were reached). Lines show the dynamics predicted by the quantitative mathe-
matical model described in the main text. (B) Experimental dose-response
curve of the PbceA promoter at a fixed time (42.5 min) after induction (sym-
bols) and the fit to the mathematical model (lines). For details, see the text.
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fluorescent protein fusions (our unpublished observations). Un-
der noninducing conditions, both proteins are below our current
detection limit and therefore not accessible to quantification.
Based on the relative promoter strengths of PbceR (see Fig. S2 in the
supplemental material) and PbceA (Fig. 2A), it could well be that
uninduced cells possess more kinases than transporters. Never-
theless, within our mathematical model we assume that the num-
ber of sensory complexes does not change over time and thus that
BceS always monitors the activity of a fixed number of transport-
ers. While this assumption might be inaccurate in the early phase
of induction, BceAB levels are expected to quickly exceed those of
BceS such that the model should well reflect the experimental
conditions shortly after induction.
Based on these considerations, we assume within our model
that BceS signals the load of individual transporters to the re-
sponse regulator BceR, such that the level of the active (phosphor-
ylated) form of BceR is proportional to the bacitracin load per
transporter, Jbac. Following a thermodynamic model for tran-
scriptional regulation (20), activation of gene expression from the
PbceA promoter by phosphorylated BceR can then be formulated in
terms of Jbac, such that the dynamic equations for bceAB mRNA




1  Jbac ⁄ n





m  BceAB (3)
Here,  is the basal transcription rate,  is the ratio of maximal
to basal promoter activity, 	 is the mRNA degradation rate, and 
is a measure of the relative flux at which PbceA is activated. The Hill
exponent (n) in turn reflects all forms of cooperativity in stimulus
perception and signal transduction, as well as in BceR-DNA bind-
ing and recruitment of RNA polymerase. Finally, 
 is the transla-
tion rate and  is the protein dilution rate due to cell doubling. The
dynamic equations for luciferase reporter expression were formu-
lated analogously to equations 2 and 3 and are given in Materials
and Methods.
We then asked whether the data in Fig. 2 were in quantitative
agreement with our mathematical model. To this end, all known
and measured model parameters were fixed to their physiological
values (see Table S1 in the supplemental material), the remaining
ones were confined to physiological intervals (see Table S2 in the
supplemental material), and then the model was fitted to the ex-
perimental dose-response in Fig. 2B (see Materials and Methods
for details of the fitting procedure). Overall, we found that the
dynamic behavior of the model closely resembled the rapid adap-
tation kinetics observed in the experimental time series (Fig. 2A).
Likewise, the model adequately captured the gradual increase of
the experimental dose-response characteristics over a wide range
of input levels (Fig. 2B). These findings provided the first quanti-
tative indication that the Bce system does in fact implement a
flux-sensing mechanism that monitors the bacitracin load per
BceAB transporter. The agreement between theory and experi-
ment in the early phase (0 to 15 min) after induction further
demonstrates that the model assumption of a constant number of
sensory complexes per cell was reasonable: if BceAB were initially
less abundant than BceS, the number of sensory complexes should
increase upon induction of BceAB production, which should re-
sult in a positive feedback on signaling. Such a positive feedback
should cause a lag in the response while the number of sensory
complexes is still very low, followed by a rapid increase in signal-
ing as more and more complexes are formed. Such an effect is not
visible in our data (Fig. 2A), showing that the window in which the
number of sensory complexes is not constant is short and cannot
be resolved by the luciferase reporter.
Predicting the signature of a relative flux sensor. One key
feature of the proposed flux sensor model is that up-regulation of
BceAB leads to a reduction of the bacitracin load per transporter,
which ultimately down-regulates transcription of bceAB. Hence, if
the model was correct, disabling this negative autoregulation of
BceAB should abolish the graded response to bacitracin. Conse-
quently, constitutively supplying the cell with a fixed number of
transporter molecules should provide an alternative means of dis-
tinguishing between the three different signaling scenarios de-
tailed above. For a relative flux-sensing mechanism, in cells with
few transporters, the load per transporter should be saturated at
low bacitracin concentrations, leading to a highly sensitive re-
sponse (Fig. 1d, right). Conversely, cells with many transporters
should respond more sluggishly (Fig. 1d, right), because more
bacitracin is required to produce a high load per transporter. For
an intracellular sensing mechanism, the opposite behavior is ex-
pected: cells with a high level of BceAB should respond more sen-
sitively than those with few transporters, as the total amount of
bacitracin translocated increases with the number of transporters
present (Fig. 1d, center). Last, for an extracellular-concentration-
sensing mechanism, the dose-response behavior should not be
affected by alterations in the level of the transporter (Fig. 1d, left).
In fact, this last situation was recently reported for the DctA/DcuS
sensor complex of E. coli (21), in which the transporter DctA
merely acts as an activity switch for the HK DcuS.
When we modified our mathematical model to accommodate
constitutive production of the transporter, the predicted dose-
response behavior was altered in two respects. First, the elimina-
tion of autoregulation of the level of BceAB results in a more
switch-like response of the PbceA promoter to increasing bacitracin
concentrations (Fig. 3a). This sharp response is due to the fact that
the fit to the data for the wild type in Fig. 2 yielded a Hill exponent
(n) of 7.5  0.2, suggesting that signal transduction and regulation
of PbceA exhibit a high degree of cooperativity. Second, when the
copy number of the transporter is changed, the model predicts a
shift in the dose-response curves consistent with the signature of a
flux sensor: in cells that constitutively express low levels of BceAB,
the promoter is triggered by low bacitracin concentrations
(Fig. 3a), while much higher concentrations of the antibiotic are
required to activate PbceA in cells that synthesize large amounts of
BceAB (Fig. 3a).
In order to test these predictions experimentally, we con-
structed a strain (SGB218) in which the endogenous bceAB locus
had been deleted, and replaced by a chromosomally integrated
construct driven by the xylose-inducible promoter PxylA. In addi-
tion, this strain carries the PbceA-luxABCDE reporter used above.
We previously quantified the dose-response characteristics of
PxylA (22). It showed a basal transcription level ~30-fold higher
than that driven by PbceA and could be activated up to ~100-fold by
increasing the xylose concentration in the medium (Fig. 3b).
Based on these data, we selected five xylose concentrations (0%,
0.005%, 0.01%, 0.03%, and 0.2%) that resulted in markedly dif-
ferent PxylA activities. Incorporation of these promoter activities
into our mathematical model led to distinct BceAB protein levels
Fritz et al.














for each xylose concentration and thus also to the parameter-free
predictions for the shifts in the activation threshold of PbceA dis-
cussed above (Fig. 3a).
Figure 3c shows the bacitracin-dependent PbceA activity of
SGB218 cells grown in the presence of the selected xylose concen-
trations. Strikingly, we found that both the theoretically predicted
abrupt onset of activation and the shift in induction threshold
with increasing xylose concentration were quantitatively reflected
in our experimental results. The latter becomes manifest, for in-
stance, when EC10 values (the bacitracin concentration at which
the dose-response reached 10% of its maximum) are plotted as a
function of xylose concentration. Theoretically, the EC10 is ex-
pected to be proportional to the concentration of BceAB in the cell
and, accordingly, to reflect the level of PxylA promoter activity
(Fig. 3b). Indeed, the experimental EC10 values all fell along this
curve (Fig. 3b), suggesting (i) that PxylA activity is in fact propor-
tional to BceAB protein levels and (ii) that the number of BceAB
transporters per cell determines how much bacitracin the cell will
tolerate before signaling is activated. To inspect the shape of the
dose-response curves in Fig. 3c more closely, we rescaled all x axes
to the EC10 values. When this was done, all dose-response curves
collapsed onto a single master curve (Fig. 3d). Remarkably, the
experimental data points showed an even steeper increase than
predicted by our model (Fig. 3d), highlighting the strong cooper-
ativity involved in signal perception, transduction, and gene reg-
ulation at PbceA. Considering that sensory perception and signal-
ing by the Bce system involve a multiprotein complex (9), it is not
difficult to envisage such strongly cooperative effects arising.
Moreover, it was previously shown that many promoters of
bceAB-like operons contain binding sites for two dimers of the
response regulator (23). Indeed, PbceA also possesses two BceR
binding sites, spaced 13 bp apart and located directly upstream of
the 10/35 promoter elements. We recently showed that both
binding sites are required for bacitracin-dependent induction of
PbceA (C. Fang and T. Mascher, unpublished data). Since each
binding site consists of a repeat sequence, each site will likely be























































































































FIG 3 Signature of a relative flux sensor. (a) Theoretical prediction of PbceA-luxABCDE dose-response curves for various levels of constitutive BceAB transporter
production (colored curves), compared to the wild type with autoregulated bceAB expression (black curve). The expression levels of bceAB in the legend are
percentages of the maximal PbceA expression level in the wild type. These expression levels were derived from the experimental dose-response curve of the PxylA
promoter in panel b, which drives expression of bceAB in the experimental system in panel c. (b) Xylose-dependent dose-response curve of a PxylA-luxABCDE
reporter strain (black symbols) published previously (22) and fitted by a Hill function (black curve). In addition, the EC10 values , i.e., concentrations at
which the dose-response curves in panel c reach 10% of their maximal activity, are shown as a function of xylose concentration (red symbols). (c)
Experimental PbceA-luxABCDE dose-response curves in strain SGB218, in which the endogenous chromosomal bceAB locus has been deleted and
transporter expression is constitutively driven from a chromosomally integrated xylose-dependent PxylA-bceAB construct (colored symbols). The wild-
type dose-response curve (black symbols) was derived from strain SGB073. (d) Data from panels a and c with the x axis rescaled by the respective EC10
values. For details, see the text.
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occupied by a dimer of BceR, indicating that a total of four BceR
molecules are required for promoter induction, which could fur-
ther enhance cooperativity in signaling.
The model successfully predicts inhibitory concentrations of
bacitracin. Bacitracin acts by binding to the lipid carrier UPP and
preventing its dephosphorylation (19). Due to its essentiality for
cell growth, a certain minimal fraction of free lipid carrier is
needed to maintain cell wall biosynthesis at a given growth rate,
and blocking a larger fraction of UPP is thus lethal. Intuitively,
expression of the BceAB transporter is expected to release UPP
from the inhibitory grip of bacitracin and thereby keep a signifi-
cant fraction of UPP bacitracin free. Hence, BceAB expression
should directly affect the bacitracin-bound UPP levels in the cell
and, with that, the cellular sensitivity to inhibition by bacitracin.
To analyze the physiological implications of the flux-sensing
mechanism, we first calculated the fraction of bacitracin-bound
UPP in the cell using our mathematical model. For the wild-type
strain employing bacitracin-dependent feedback regulation of
bceAB expression, the fraction of bacitracin-bound UPP first in-
creases rapidly with the applied concentration of the antibiotic
(Fig. 4a). As soon as BceS detects a significant bacitracin flux via
the BceAB transporter (at ca. 0.3 g/ml bacitracin), transporter
production is up-regulated and the rate of accumulation of
bacitracin-bound UPP is slowed. Based on the bacitracin concen-
tration needed to inhibit the growth of the wild type (ca. 200 g/
ml), we calculated the lethal fraction of bacitracin-bound UPP to
be 90% (Fig. 4a). In the absence of BceAB transporters, our model
predicted that the fraction of bacitracin-bound UPP increases
rapidly with the applied bacitracin concentration and reaches the
lethal 90% threshold at 2 g/ml bacitracin (Fig. 4a). This is slightly
below the experimentally determined MIC of 8 to 16 g/ml for a
strain with bceAB deleted. However, the difference is not surpris-
ing given that the model does not take into account residual bac-
itracin resistance caused, e.g., by the UPP phosphatase BcrC and
other members of the M, X, and W regulons involved in the
response of B. subtilis to cell envelope stress (24–26). In contrast to
the homeostatic control seen in the wild type, for the strain with
constitutive bceAB expression, the model predicted the binding
curve to be of the same shape as in the absence of BceAB. However,
the curves were shifted to ever-higher bacitracin concentrations
the more transporter was present in the cell (Fig. 4a). Hence, the
model also predicted that the higher the level of BceAB, the greater
the antibiotic concentration required for killing (Fig. 4a).
To confront these predictions with experimental data, we as-
sayed the reporter strains for growth inhibition by bacitracin. For
this, growth rates were determined after addition of a range of
bacitracin concentrations to exponentially growing cultures pro-
ducing different levels of transporter. For each culture, increasing
the added concentration of bacitracin first led to a significant de-
crease in growth rate (Fig. 4b) and eventually to complete cessa-
tion of growth or cell lysis, with higher concentrations being re-
quired to inhibit cells expressing bceAB at higher levels. Prediction
of the lethal threshold concentration by the model approximately
reproduced the observed relationship between growth inhibition
and bceAB expression (dashed line in Fig. 4b). The steeper decline
of the theoretical curve compared to the experimental data at low
levels of BceAB can again be explained by the presence of alterna-
tive resistance determinants in B. subtilis, as discussed above.
When we adjusted the model to the background resistance of a
bceAB deletion-containing strain (here, 15 g/ml), it accurately
described the correlation between BceAB expression levels and
inhibitory bacitracin concentration (solid line in Fig. 4b).
Our model does not distinguish between the cellular concen-
tration of UPP-bacitracin complexes (i.e., the assumed transport
substrate) and the true transport flux as input parameters, because
binding kinetics and transport activity are mathematically equiv-
alent in the Michaelis-Menten equation employed. This consider-
ation becomes important in light of the possibility that BceAB
might serve as a sensor without actually translocating any of its
substrate. However, if BceAB were transport deficient, the con-
centration of UPP-associated bacitracin should always be propor-
tional to the extracellular antibiotic concentration, regardless of
the number of functional transporters in the cell. This is entirely
inconsistent with the shifts in dose-response curves observed in



































































FIG 4 Inhibition of cell wall biosynthesis by blocking UPP recycling. (a)
Change in the fraction of bacitracin-bound UPP as a function of external
bacitracin, predicted by a model with feedback regulation (black curve) and a
model with the indicated levels of constitutive bceAB expression (colored
curves). In addition to the bceAB expression levels used in Fig. 3, the red curve
shows the percentage of bacitracin-bound UPP in the absence of the BceAB
transporter. Assuming that cell wall biosynthesis can be maintained as long as
the percentage of blocked UPP carrier molecules remains below a given limit
(dashed grey line), the intersection with the solid lines leads to a prediction of
how the bacitracin MIC should scale with increasing BceAB expression level
(dashed grey line in panel b). (b) Growth inhibition of strain SGB218 with
constitutive transporter expression from a xylose-dependent PxylA-bceAB con-
struct (colored symbols). Cultures with a low bceAB expression level (0% xy-
lose) are more susceptible to bacitracin than cultures with a high bceAB ex-
pression level (0.2% xylose). The model quantitatively captures the scaling of
this growth inhibition line (solid grey line), when background resistance
mechanisms, which are reflected in an additive offset for low bceAB expression
level, are taken into account.
Fritz et al.














the good fit between observed growth inhibition by bacitracin and
predicted lethal threshold at different transporter expression lev-
els (Fig. 4) showed that the transporter indeed had an impact on
the fraction of bacitracin-bound UPP and thus must be able to
translocate its substrate.
Taken together, our theoretical and experimental data clearly
indicate that a combination of relative flux sensing and concom-
itant negative feedback provides efficient homeostatic control
over the level of bacitracin-bound UPP, allowing it to be main-
tained below the lethal concentration threshold over a range of
antibiotic concentrations covering at least two orders of magni-
tude.
DISCUSSION
Bacteria can perceive their environment either directly, by moni-
toring the concentration of a relevant substance, or indirectly, by
monitoring the effects on cellular physiology caused by a particu-
lar condition. We show here that sensing of transport flux of an-
timicrobial substances through a resistance pump presents a third
and novel sensing strategy, by which the cell can directly monitor
and respond to its current detoxification capacity. Through quan-
titative, time-resolved analysis of the dose-response dynamics,
combined with mathematical modeling of the regulatory path-
way, we obtained evidence that the Bce system of B. subtilis imple-
ments such a flux sensor, where the parameter monitored by the
signaling system is the activity of individual BceAB transporters.
This elegant mechanism permits continual assessment of the most
critical parameter of antibiotic resistance, i.e., the cell’s current
capacity to deal with the inhibitory effects of the applied drug.
From a systems perspective, this parameter is far more relevant to
the cell than the present concentration of the antibiotic: as long as
the cell’s transport capacity is sufficient to detoxify the drug, there
is no need for a further response even at high antibiotic concen-
trations. We therefore propose that flux sensing is a very cost-
efficient regulatory strategy to control antibiotic resistance. To
our knowledge, this is the first report of such a regulatory mech-
anism in any physiological context.
Over 200 Bce-like systems can currently be found in protein
databases, and their components were shown to have coevolved
(23). Combined with experimental confirmation of the transport-
er’s sensory role in all systems studied to date (8, 11, 27–29), this
tight evolutionary correlation suggests conservation of the signal-
ing mechanism. Flux sensing may therefore be a widespread reg-
ulatory principle in antimicrobial peptide resistance. Because this
mechanism relies on the intricate process of communicating
transport flux between proteins, it should, conceivably, be easy to
disrupt and thus might constitute a prime drug target to counter-
act resistance in pathogenic bacteria possessing Bce-like systems,
such as S. aureus, E. faecalis, Listeria monocytogenes, and Clostrid-
ium difficile (8, 23, 27, 30).
Our modeling approach not only has provided evidence for a
flux-sensing mechanism but also has given access to important
system variables that are difficult to quantify experimentally, most
notably the fraction of bacitracin-bound UPP. Analysis of such
“hidden” parameters can lead to highly relevant predictions for
bacterial physiology, such as our calculation of the dependence
between the bacitracin concentration required to inhibit growth
and the expression level of the resistance determinant. Ultimately,
such an approach may have important implications for the treat-
ment of infectious disease caused by drug-resistant bacteria. Im-
portantly, Bce-like systems have been shown to respond to a large
variety of peptide antibiotics that interfere with different stages of
cell wall synthesis, including lantibiotics such as nisin, but also the
clinically relevant glycopeptides vancomycin and teicoplanin (6,
31, 32).
In summary, we report the first observation of transport flux
sensing as an elegant way of implementing adaptation via negative
feedback regulation. We propose that this represents a highly cost-
efficient mode of gene regulation, finely adjusted to the current
physiological needs of the cell. In the case of antibiotic resistance
mediated by Bce-like systems, this need is an increased demand
for detoxification. Future exploration of further systems employ-
ing transporters to control a signaling pathway will show if this
mechanism can also be found in other physiological contexts.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All strains used in this study are
listed in Table S3 in the supplemental material. Strains were routinely
propagated in Luria-Bertani (LB) medium. For all functional assays,
B. subtilis was grown in chemically defined CSE medium (33), in which
the carbon source was modified to provide constant growth rates over an
extended period of time [3.3 g/liter (NH4)2SO4, 29 mM KH2PO4, 70 mM
K2HPO4, 1 III= salts (100 III= salts is 0.232 g/liter MnSO4·4H2O,
12.3 g/liter MgSO4·7H2O), 50 mg/liter tryptophan, 22 mg/liter ammo-
nium ferric citrate, 0.8% (wt/vol) potassium glutamate, 0.6% (wt/vol)
sodium succinate, 2.5% (wt/vol) fructose]. Selective medium for B. sub-
tilis contained kanamycin (10 mg/liter), chloramphenicol (5 mg/liter) or
erythromycin (1 mg/liter) in combination with lincomycin (25 mg/liter)
for macrolide-lincosamide-streptogramin B resistance (MLSr). Selective
medium for E. coli contained ampicillin (100 mg/liter). Solid medium
additionally contained 1.5% (wt/vol) agar.
Construction of plasmids and strains. All cloning was performed ac-
cording to BioBrick standard RFC10 (http://hdl.handle.net/1721.1/
45138) or RFC25 (http://hdl.handle.net/1721.1/45140). Plasmids, strains,
and primer sequences are listed in Table S3 in the supplemental material.
The bceAB operon of B. subtilis was adapted to the BioBrick standard by
addition of prefix and suffix sequences according to a modified RFC25
standard (22) using PCR (primers TM2577 and TM2578). All internal
PstI sites were changed from CTGCAG to CTCCAG and EcoRI sites from
GAATTC to GAGTTC by PCR overlap extension mutagenesis (34). Point
mutations were chosen so to avoid any change in the encoded protein
sequence. Cloning of the resulting fragment into the EcoRI and SpeI sites
of pSB1A3 resulted in pNTSB103. The PxylA region of pXT was adapted for
BioBrick cloning by the addition of RFC10 prefix and suffix sequences via
PCR (primers iGEM134 and iGEM135) and cloning into the EcoRI and
SpeI sites of pSB1A3, to generate pNTSB104. Subsequently, the bceAB
operon was placed under the transcriptional control of PxylA by BioBrick
assembly of the pNTSB103 and pNTSB104 inserts into the vector pBS2E
(22), resulting in pNT2E01. To quantify target promoter activities, wild-
type B. subtilis W168 was transformed with a transcriptional PbceA-
luxABCDE reporter construct, pSDlux101 (35), producing strain
SGB073. Introduction of the same reporter together with pNT2E01 into
the bceAB::Kan deletion strain TMB035 produced strain SGB218.
Luciferase assays. Luciferase activities were assayed using a Synergy2
multimode microplate reader from BioTek (Winooski, VT) controlled by
the software Gen5. Aliquots of culture (100 l) were added to 96-well
plates (black walls, clear bottoms; Greiner Bio-One, Frickenhausen, Ger-
many), which were incubated at 37°C with medium-intensity agitation.
Cell growth was monitored by measuring optical density at 600 nm
(OD600). For each individual sample, the OD600 and relative lumines-
cence units (RLU) (endpoint reads; 1-s integration time; sensitivity, 200)
were background corrected by subtracting the respective values measured
for wells containing 100 l of CSE medium. RLU/OD600 values were
calculated for individual measurements. Means and standard deviations
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of RLU/OD600 values were determined from at least three biological rep-
licates.
To synchronize cultures, 10 ml of CSE medium in a 125-ml flask was
inoculated with 0.2 ml of an overnight culture and incubated at 37°C with
agitation (200 rpm) to an OD600 of 0.2 to 0.5. Cultures were then diluted
in fresh CSE medium to an OD600 of 0.05 and transferred to 96-well plates.
OD600 and luminescence were monitored every 10 min, and at an OD600
of ~0.1 (corresponding to an OD600 of ~0.4 in cuvettes with a 1-cm light
path length), 5 l of Zn2 bacitracin was added to give the final concen-
trations indicated in the figure legends. Incubation was continued, and
OD600 and luminescence were monitored every 5 min for 1 h. For con-
trolled expression of bceAB in strain SGB218, xylose was added to all
growth media at the final concentrations indicated in the figure legends.
Bacitracin sensitivity assays. The MIC of bacitracin for B. subtilis
grown in CSE medium was determined by a broth dilution technique.
Cultures were grown to stationary phase in CSE medium and then diluted
(1:500) into fresh CSE medium containing different concentrations of
Zn2 bacitracin. Following 20 to 24 h of incubation at 37°C with agitation,
the MIC was scored as the lowest concentration at which no growth was
observed. Inhibition of growing cultures (Fig. 4b) was determined as fol-
lows. Cells of strain SGB218 were cultured with the indicated xylose con-
centrations and challenged with the final concentrations of Zn2 bacitra-
cin indicated in the figure legends as described for the luciferase assays
above. Average growth rates () were estimated from an exponential fit to
the growth curve (OD600) from 0 h (bacitracin addition) to 1 h for each
experimental condition. Growth inhibition was calculated as 1  (/
max), where max is the maximal growth rate at a given xylose concentra-
tion.
Mathematical model and parameter estimation. The minimal model
for the dynamics of the bceAB operon in the wild-type strain SGB073 is
described by equations 1 to 3. In constructing this model we made the
simplifying assumption that the maximal amount of UPP in a cell, UPPtot,
is given by the sum of all intermediate forms of the lipid carrier molecule
present in the cell (see Table S1 in the supplemental material for param-
eter values). Binding of bacitracin to UPP then leads to the accumulation
of the bacitracin-bound form of UPP, UPP-bac, to the maximal amount
(UPPtot). To model the constitutive expression of bceAB in strain SGB218,
the flux-dependent transcription rate in equation 2 was replaced by a
temporally constant transcription rate, which is determined solely by the
concentration of externally supplied xylose:
d
dt
m  xyl  	m (4)
The xylose-dependent rate of bceAB transcription driven by PxylA was
modeled as xyl    f(xyl)/g(bac0), where  is the rate of PbceA-
controlled transcription in the absence of bacitracin and f(xyl) and g(bac)
are the experimental dose-response curves for PxylA (Fig. 3b) and PbceA
(Fig. 2B), respectively. In addition, expression of the luxABCDE reporter
genes in all strains is under the control of an ectopically integrated PbceA
promoter, which is assumed to follow the same transcriptional kinetics as




1  Jbac ⁄ n
1  Jbac ⁄ n
 	luxmlux (5)
Here, mlux is the luxABCDE mRNA, 	lux is the associated degradation
rate, and all other parameters are the same as in equation 2. Assuming that
one of the proteins in the lux operon is rate limiting for light production,




mlux  luxLux (6)
where 
 is the translation rate and lux is the corresponding protein
half-life. In addition, a multiplicative scaling factor, , was introduced to
relate the Lux protein level to the experimentally measured luminescence
output.
To fit the model to our experimental data, the parameters were fixed to
physiological values whenever possible (see Table S1 in the supplemental
material) and constrained to physiologically reasonable intervals in all
other cases (see Table S2 in the supplemental material). Then, a trust
region-reflective Newton method (MatLab; The MathWorks, Inc.) was
used to minimize the value of 2 between the dose-response curve in
Fig. 2B and the model. To account for the presence of local optima and to
quantify the uncertainty in the estimated parameters, 100 independent fits
were performed with randomly chosen initial parameter sets (see Fig. S4
and S5 in the supplemental material for correlation graphs between 2 and
estimated parameters). Confidence intervals for the fitted parameters (see
Table S2) were obtained as previously described (36). The prediction of
the dose-response curves for strain SGB218 was based on the parameter
set from strain SGB073, but calculated using equation 4 instead of equa-
tion 2.
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11. Staroń A, Finkeisen DE, Mascher T. 2011. Peptide antibiotic sensing and
detoxification modules of Bacillus subtilis. Antimicrob Agents Chemother
55:515–525. http://dx.doi.org/10.1128/AAC.00352-10.
12. Hasty J, McMillen D, Isaacs F, Collins JJ. 2001. Computational studies of
gene regulatory networks: in numero molecular biology. Nat Rev Genet
2:268 –279. http://dx.doi.org/10.1038/35066056.
13. Rosenfeld N, Elowitz MB, Alon U. 2002. Negative autoregulation speeds
the response times of transcription networks. J Mol Biol 323:785–793.
http://dx.doi.org/10.1016/S0022-2836(02)00994-4.
14. Island MD, Kadner RJ. 1993. Interplay between the membrane-
associated UhpB and UhpC regulatory proteins. J Bacteriol 175:
5028 –5034.
15. Schwöppe C, Winkler HH, Neuhaus HE. 2003. Connection of transport
and sensing by UhpC, the sensor for external glucose-6-phosphate in
Escherichia coli. Eur J Biochem 270:1450 –1457. http://dx.doi.org/10.1046/
j.1432-1033.2003.03507.x.
16. Schleif R. 2000. Regulation of the L-arabinose operon of Escherichia coli.
Trends Genet 16:559 –565. http://dx.doi.org/10.1016/S0168
-9525(00)02153-3.
17. Chang G. 2003. Multidrug resistance ABC transporters. FEBS Lett 555:
102–105. http://dx.doi.org/10.1016/S0014-5793(03)01085-8.
18. Ohki R, Giyanto, Tateno K, Masuyama W, Moriya S, Kobayashi K,
Ogasawara N. 2003. The BceRS two-component regulatory system in-
duces expression of the bacitracin transporter, BceAB, in Bacillus subtilis.
Mol Microbiol 49:1135–1144. http://dx.doi.org/10.1046/j.1365
-2958.2003.03653.x.
19. Storm DR, Strominger JL. 1973. Complex formation between bacitracin
peptides and isoprenyl pyrophosphates. The specificity of lipid-peptide
interactions. J Biol Chem 248:3940 –3945.
20. Bintu L, Buchler NE, Garcia HG, Gerland U, Hwa T, Kondev J, Phillips
R. 2005. Transcriptional regulation by the numbers: models. Curr Opin
Genet Dev 15:116 –124. http://dx.doi.org/10.1016/j.gde.2005.02.007.
21. Steinmetz PA, Wörner S, Unden G. 2014. Differentiation of DctA and
DcuS function in the DctA/DcuS sensor complex of Escherichia coli: func-
tion of DctA as an activity switch and of DcuS as the C4-dicarboxylate
sensor. Mol Microbiol 94:218 –229. http://dx.doi.org/10.1111/
mmi.12759.
22. Radeck J, Kraft K, Bartels J, Cikovic T, Dürr F, Emenegger J, Kelterborn
S, Sauer C, Fritz G, Gebhard S, Mascher T. 2013. The Bacillus BioBrick
box: generation and evaluation of essential genetic building blocks for
standardized work with Bacillus subtilis. J Biol Eng 7:29. http://dx.doi.org/
10.1186/1754-1611-7-29.
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